Jia-hai Lee

Array ( [id] => 16710482 [patent_doc_number] => 20210077629 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => IMPROVED PEPTIDE PHARMACEUTICALS [patent_app_type] => utility [patent_app_number] => 16/579799 [patent_app_country] => US [patent_app_date] => 2019-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56444 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16579799 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16253540 [patent_doc_number] => 20200262914 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-20 [patent_title] => PEPTIDES SELECTIVE FOR BCL-2 FAMILY PROTEINS [patent_app_type] => utility [patent_app_number] => 16/573881 [patent_app_country] => US [patent_app_date] => 2019-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28613 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16573881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16178272 [patent_doc_number] => 20200225240 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-16 [patent_title] => USE OF CD36 TO IDENTIFY CANCER SUBJECTS FOR TREATMENT [patent_app_type] => utility [patent_app_number] => 16/549961 [patent_app_country] => US [patent_app_date] => 2019-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11928 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16549961 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15493239 [patent_doc_number] => 20200046808 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-13 [patent_title] => DILUTE SURFACTANT OR ISOLATED SURFACTANT PROTEIN SOLUTION FOR THE REDUCTION OF SURFACE TENSION IN THE LUNG [patent_app_type] => utility [patent_app_number] => 16/542169 [patent_app_country] => US [patent_app_date] => 2019-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6004 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -63 [patent_words_short_claim] => 151 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16542169 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15586471 [patent_doc_number] => 20200069770 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER EYE DISEASES WITH APOLIPOPROTEIN MIMETICS [patent_app_type] => utility [patent_app_number] => 16/542261 [patent_app_country] => US [patent_app_date] => 2019-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49847 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16542261 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16970481 [patent_doc_number] => 11066442 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-20 [patent_title] => Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation [patent_app_type] => utility [patent_app_number] => 16/526862 [patent_app_country] => US [patent_app_date] => 2019-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 20 [patent_no_of_words] => 22276 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16526862 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15828631 [patent_doc_number] => 20200129597 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-30 [patent_title] => MODULATION OF FACTOR Xa INHIBITOR-MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIDOTE [patent_app_type] => utility [patent_app_number] => 16/519732 [patent_app_country] => US [patent_app_date] => 2019-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16864 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16519732 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15035639 [patent_doc_number] => 20190328824 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => HYDROGEL COMPOSITION AND ASSOCIATED METHOD OF USE [patent_app_type] => utility [patent_app_number] => 16/510381 [patent_app_country] => US [patent_app_date] => 2019-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19628 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16510381 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19089746 [patent_doc_number] => 11951165 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-09 [patent_title] => Conjugated vaccine carrier proteins [patent_app_type] => utility [patent_app_number] => 16/459303 [patent_app_country] => US [patent_app_date] => 2019-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 94230 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16459303 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15320785 [patent_doc_number] => 20200000722 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-02 [patent_title] => SYNTHETIC POLYPEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/455800 [patent_app_country] => US [patent_app_date] => 2019-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14091 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 360 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16455800 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15020889 [patent_doc_number] => 20190321449 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-24 [patent_title] => Blood Plasma Fractions as a Treatment for Aging-Associated Cognitive Disorders [patent_app_type] => utility [patent_app_number] => 16/456717 [patent_app_country] => US [patent_app_date] => 2019-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19500 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16456717 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15239549 [patent_doc_number] => 20190374560 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-12 [patent_title] => SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/450836 [patent_app_country] => US [patent_app_date] => 2019-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40644 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16450836 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16791717 [patent_doc_number] => 20210121534 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-29 [patent_title] => SUSTAINED-RELEASE DRUG DELIVERY SYSTEMS COMPRISING AN INTRAOCULAR PRESSURE LOWERING AGENT, A CNP COMPOUND, AN NPR-B COMPOUND, A TIE-2 AGONIST, OR NEUROTROPHIC AGENT FOR USE FOR TREATING GLAUCOMA OR OCULAR HYPERTENSION [patent_app_type] => utility [patent_app_number] => 17/254617 [patent_app_country] => US [patent_app_date] => 2019-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21009 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17254617 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15264447 [patent_doc_number] => 20190380957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-19 [patent_title] => Protein Hydrogels For Treatment Of Neovascular Disease [patent_app_type] => utility [patent_app_number] => 16/442044 [patent_app_country] => US [patent_app_date] => 2019-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5897 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16442044 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15649631 [patent_doc_number] => 20200087345 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => MODULATION OF P53 FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/422850 [patent_app_country] => US [patent_app_date] => 2019-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29764 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16422850 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14864869 [patent_doc_number] => 20190282676 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => HEMOSTATIC COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 16/421094 [patent_app_country] => US [patent_app_date] => 2019-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10567 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16421094 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15035653 [patent_doc_number] => 20190328831 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1 [patent_app_type] => utility [patent_app_number] => 16/411944 [patent_app_country] => US [patent_app_date] => 2019-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10589 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16411944 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16868433 [patent_doc_number] => 20210161900 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF SENESCENT TUMOR CELLS [patent_app_type] => utility [patent_app_number] => 17/047258 [patent_app_country] => US [patent_app_date] => 2019-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10686 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -51 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17047258 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16596582 [patent_doc_number] => 20210023113 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => CONJUGATE OF CYTOTOXIC DRUG AND PRODRUG FORM OF SAID CONJUGATE [patent_app_type] => utility [patent_app_number] => 17/042221 [patent_app_country] => US [patent_app_date] => 2019-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12469 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17042221 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16343578 [patent_doc_number] => 20200308228 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => PEPTIDE INHIBITORS OF HCV NS3/4A PROTEASE COMPRISING NON-PROTEINOGENIC AMINO RESIDUES [patent_app_type] => utility [patent_app_number] => 16/371610 [patent_app_country] => US [patent_app_date] => 2019-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14610 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 168 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16371610 [rel_patent_id] =>[rel_patent_doc_number] =>)